Management of Thyroid carcinoma: Hahnemann experience
(ندگان)پدیدآور
Dadparvar, SiminLahaniatis, JohnAsrari, FaribaShaikh, AtharGhesani, NasrinTulchinsky, MarkSlizofski, WalterBrady, Lutherنوع مدرک
TextOriginal Article
زبان مدرک
Englishچکیده
The primary treatment of thyroid carcinoma is surgery and the outcome depends on its extent. The post-operative management alternatives in thyroid carcinoma include thyroid hormone, radio-iodine ablation (I-131 Na), external beam radiation therapy (EBRT) and occasionally adjuvant chemotherapy. This retrospective study analyzes the managements of 153 patients (102, 51), age range 10-96 years, mean age 50.2 years treated for thyroid carcinoma. The range of follow-up was 1.0-294 months with median follow-up for 60.4 months. Twenty patients without therapy were excluded. Group A included 87 patients treated with I-131. Group B consisted of 13 patients received EBRT. Group C included both therapies in 33 patients. The therapies in all different stages of thyroid carcinoma and with various histopathologies were reviewed.
کلید واژگان
Nuclear Medicineشماره نشریه
1تاریخ نشر
2001-12-011380-09-10
ناشر
Research Center for Nuclear Medicine (Tehran University of Medical Sciences)سازمان پدید آورنده
Division of Nuclear Medicine, Department of Radiation Oncology and Nuclear Medicine, Hahnemann University, Philadelphia, PA, USADivision of Nuclear Medicine, Department of Radiation Oncology and Nuclear Medicine, Hahnemann University, Philadelphia, PA, USA
Division of Nuclear Medicine, Department of Radiation Oncology and Nuclear Medicine, Hahnemann University, Philadelphia, PA, USA
Division of Nuclear Medicine, Department of Radiation Oncology and Nuclear Medicine, Hahnemann University, Philadelphia, PA, USA
Division of Nuclear Medicine, Department of Radiation Oncology and Nuclear Medicine, Hahnemann University, Philadelphia, PA, USA
Division of Nuclear Medicine, Department of Radiation Oncology and Nuclear Medicine, Hahnemann University, Philadelphia, PA, USA
Division of Nuclear Medicine, Department of Radiation Oncology and Nuclear Medicine, Hahnemann University, Philadelphia, PA, USA
Division of Nuclear Medicine, Department of Radiation Oncology and Nuclear Medicine, Hahnemann University, Philadelphia, PA, USA
شاپا
1681-28242008-2509




